Education
About Us
Working with TipRanks
Follow Us
Almirall SA (GB:0O9B)
LSE:0O9B
0O9B Stock Chart & Stats
€12.90
-€0.04(-0.52%)
At close: 4:00 PM EST
€12.90
-€0.04(-0.52%)
Day’s Range― - ―
52-Week Range€8.74 - €13.98
Previous CloseN/A
Volume457.00
Average Volume (3M)2.60K
Market Cap
€2.46B
Enterprise Value€2.41B
Total Cash (Recent Filing)€338.82M
Total Debt (Recent Filing)€342.86M
Price to Earnings (P/E)35.1
Beta1.06
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding214,785,200
10 Day Avg. Volume4,186
30 Day Avg. Volume2,602
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.85
Price to Sales (P/S)2.49
P/FCF Ratio20.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.77Price Target Upside6.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.45
Revenue Forecast (FY)€1.24B
Bulls Say, Bears Say
Bulls Say
Revenue & Profit RecoveryAlmirall returned to revenue growth and positive operating profit in 2025, signaling a durable inflection versus prior loss years. Sustained top-line recovery paired with positive margins supports longer-term cash generation and reinvestment capacity for dermatology R&D and commercialization over the next 2–6 months.
Manageable LeverageImproving debt-to-equity and a stable equity base give Almirall financial flexibility. Lower leverage reduces refinancing and interest-rate risk, enabling funding for strategic initiatives, partnerships or targeted M&A while preserving the balance sheet over a multi-month horizon.
Cash-flow ReboundA clear rebound in operating cash flow and positive free cash flow in 2025 is a constructive structural signal. Improved cash generation supports discretionary spending on R&D, potential partner deals and shareholder returns, and reduces reliance on external financing in the medium term.
Bears Say
Earnings & FCF VolatilityHistorical swings between losses and profits and unstable FCF undermine predictability of cash available for reinvestment or returns. This volatility raises execution risk, complicates multi-period planning for portfolio investment and increases sensitivity to commercial setbacks or reimbursement shifts.
Low Returns On EquityA low ROE indicates the balance sheet has not translated into commensurate profitability. Persistent low returns constrain long-term shareholder value creation and suggest limited efficiency in deploying capital compared with higher-return peers in specialty pharma.
Uneven Profitability And Thin MarginsAlthough margins recovered in 2025, historical uneven earnings and generally thin net margins highlight limited structural profitability. Fragile margin levels increase vulnerability to pricing, competitive generics and reimbursement pressures, making durable margin expansion uncertain.
Almirall News
0O9B FAQ
What was Almirall SA’s price range in the past 12 months?
Almirall SA lowest share price was €8.74 and its highest was €13.98 in the past 12 months.
What is Almirall SA’s market cap?
Almirall SA’s market cap is €2.46B.
When is Almirall SA’s upcoming earnings report date?
Almirall SA’s upcoming earnings report date is May 11, 2026 which is in 52 days.
How were Almirall SA’s earnings last quarter?
Almirall SA released its earnings results on Feb 23, 2026. The company reported €0.091 earnings per share for the quarter, missing the consensus estimate of €0.16 by -€0.069.
Is Almirall SA overvalued?
According to Wall Street analysts Almirall SA’s price is currently Undervalued.
Does Almirall SA pay dividends?
Almirall SA does not currently pay dividends.
What is Almirall SA’s EPS estimate?
Almirall SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Almirall SA have?
Almirall SA has 214,785,200 shares outstanding.
What happened to Almirall SA’s price movement after its last earnings report?
Almirall SA reported an EPS of €0.091 in its last earnings report, missing expectations of €0.16. Following the earnings report the stock price went down -5.821%.
Which hedge fund is a major shareholder of Almirall SA?
Currently, no hedge funds are holding shares in GB:0O9B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Almirall Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€13.77 (6.72% Upside)
€13.77 (6.72% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.06%
12-Months-Change
Fundamentals
Return on Equity
3.96%
Trailing 12-Months
Asset Growth
-2.48%
Trailing 12-Months
Company Description
Almirall SA
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
0O9B Stock 12 Month Forecast
Average Price Target
€13.77
▲(6.72% Upside)
Technical Analysis
Faes Farma
―
Grifols
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
Options Prices
Currently, No data available
---